Second leading cause of cancer mortality in the US.
Uncommon in men aged under 50 years.
PSA and digital rectal examination are key diagnostic tools used in screening.
Management may be expectant or definitive.
The overall 5-year relative survival rate for 2002 to 2008 was 96% to 100%, but this varies greatly depending on the National Comprehensive Cancer Network (NCCN) risk category.
A malignant tumor of glandular origin, situated in the prostate. It is most commonly seen in older men; between 2000 and 2004 the median age at diagnosis of prostate cancer in the US was 68 years of age.  Prostate cancer is graded by the Gleason score (the sum of 2 scales scored 1 to 5 that designates the degree of differentiation of the tumor's predominant cell lines).
Richmond Radiation Oncology Associates
Bon Secours Cancer Institute
TJW declares that he is the Principle Investigator of an R-21 NIH research grant investigating the tumor-mediated immune responses in African-American men with prostate cancer.
Department of Radiation Oncology
University of Texas MD Anderson Cancer Center
MSA declares that he has no competing interests.
Clinical Oncology Registrar
St Luke's Cancer Centre
Royal Surrey Hospital
EA has received consultation fees from the following organizations during the past 3 years: Blue Cross/Blue Shield Association, Sanofi-Aventis, Ferring Pharmaceuticals, Pfizer Corporation, American Urological Association, National Institutes of Health, Accreditation Council for Graduate Medical Education, Royal Hallamshire Hospital, Hartford County Medical Association. EA owns shares in Pfizer Pharmaceuticals, Johnson and Johnson, and General Electric Corporation.
UConn Medical Group
University of Connecticut Health Center
PA declares that he has no competing interests.
Use of this content is subject to our disclaimer